Spain's plans to consolidate its IPT assessment arrangements faced delays due to legal challenges, reflecting difficulties in changing infrastructure. The intention was to introduce a formal economic analysis combined with clinical appraisals, similar to other established models. However, despite setbacks, there remains a shift towards emphasizing cost-effectiveness data and exploring innovative contracting, like risk-sharing outcome-based agreements, for medicines in Spain.